Lenzilumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLenzilumab
Drug Alias Name仑兹鲁单抗lenzilumabum兰泽人单抗KB-003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionMacrophage colony stimulating factor 2 inhibitors
TargetsMacrophage colony stimulating factor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, RheumatoidLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomBrazil +[4] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesKalobios
China Registration ClassN/A

Develop Information

Active CompaniesTaran Therapeutics IncKpm Tech Co LtdHumanigen Inc +[4] 
Inactive CompaniesKite Pharma
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsArthritis, RheumatoidLymphoma, Large B-Cell, DiffuseLeukemia, Myelomonocytic, Chronic

Other Information

ATC CodeN/A
Related LinksWikipedia